Open Label Study of Duloxetine for the Treatment of Phantom Limb Pain

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-01-31

Study Completion Date

2007-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a study to assess the possible benefit of duloxetine in the treatment of chronic phantom limb pain.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome

NCT00004832

Lambert-Eaton Myasthenic Syndrome

COMPLETED NA

3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)

NCT00872950

Lambert-Eaton Myasthenic Syndrome Congenital Myasthenic Syndrome

APPROVED_FOR_MARKETING

Phase II Clinical Trial of Clenbuterol in Adult Patients With Pompe Disease

NCT04094948

Pompe Disease (Late-onset)

WITHDRAWN PHASE2

Clinical Trial of Sodium Phenylbutyrate in Children With Spinal Muscular Atrophy Type I

NCT00439218

Spinal Muscular Atrophy Type I

TERMINATED PHASE1/PHASE2

Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases

NCT01472263

HTLV-1 Tropical Spastic Paraparesis Immune System Diseases +2 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Phantom Limb Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Duloxetine

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Chronic PLP \> 6 months
2. Short-Form McGill Pain Questionnaire Sensory Pain Rating Index raw score ≥ 16
3. Age ≥ 18 years old
4. Inpatient or Outpatient
5. Able to come to all appointments, in the opinion of the investigator
6. Able to give informed consent, in opinion of investigator

Exclusion Criteria

1. Current Major Depressive disorder, Anxiety Disorder, or Psychotic disorder assessed by the Mini International Neuropsychiatric Interview (MINI)
2. Substance abuse or dependence within the last six months, as assessed by the MINI
3. Known Diabetes Mellitus to exclude diabetic peripheral neuropathy
4. History of coronary artery disease, hepatic disease, renal disease
5. Other pain syndromes
6. Any unstable medical conditions in the opinion of the investigator
7. Other psychotropic medications excluding hypnotics

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes